Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Bjorkholm

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
European Journal of Haematology|April 21, 2018
Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survivalIngemar Turesson, Magnus Bjorkholm, Cecilie Hveding Blimark, et al.
Blood|July 29, 2011
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Sham Mailankody, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Cancer|April 28, 2006
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of lifeJan Samuelsson, Hans Hasselbalch, Oystein Bruserud, et al.
Blood|February 3, 2009
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in SwedenOla Landgren, Sigurdur Y Kristinsson, Lynn R Goldin, et al.
Archives of Pathology & Laboratory Medicine|August 30, 2014
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617FNataliya Vytrva, Elvira Stacher, Peter Regitnig, et al.
Oncotarget|April 19, 2017
The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinomaXiaotian Yuan, Guanghui Cheng, Jingya Yu, et al.
Nature Reviews. Disease Primers|May 10, 2016
Acute myeloid leukaemiaAsim Khwaja, Magnus Bjorkholm, Rosemary E Gale, et al.
The American Journal of Pathology|May 27, 2008
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cellsKarl R N Baumforth, Anna Birgersdotter, Gary M Reynolds, et al.
Acta Haematologica|May 5, 2005
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-upBengt Simonsson, Gunnar Oberg, Mats Bjoreman, et al.
Haematologica|January 11, 2024
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and SwedenSæmundur Rögnvaldsson, Sigrun Thorsteinsdóttir, Elisavet Syriopoulou, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
European Journal of Haematology|April 21, 2018
Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survivalIngemar Turesson, Magnus Bjorkholm, Cecilie Hveding Blimark, et al.
Blood|July 29, 2011
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Sham Mailankody, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Cancer|April 28, 2006
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of lifeJan Samuelsson, Hans Hasselbalch, Oystein Bruserud, et al.
Blood|February 3, 2009
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in SwedenOla Landgren, Sigurdur Y Kristinsson, Lynn R Goldin, et al.
Archives of Pathology & Laboratory Medicine|August 30, 2014
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617FNataliya Vytrva, Elvira Stacher, Peter Regitnig, et al.
Oncotarget|April 19, 2017
The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinomaXiaotian Yuan, Guanghui Cheng, Jingya Yu, et al.
Nature Reviews. Disease Primers|May 10, 2016
Acute myeloid leukaemiaAsim Khwaja, Magnus Bjorkholm, Rosemary E Gale, et al.
The American Journal of Pathology|May 27, 2008
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cellsKarl R N Baumforth, Anna Birgersdotter, Gary M Reynolds, et al.
Acta Haematologica|May 5, 2005
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-upBengt Simonsson, Gunnar Oberg, Mats Bjoreman, et al.
Haematologica|January 11, 2024
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and SwedenSæmundur Rögnvaldsson, Sigrun Thorsteinsdóttir, Elisavet Syriopoulou, et al.
Pageof 1